Published in Clinical Oncology Week, May 8th, 2006
The findings from the international multicenter trial in 187 men showed that 100% of those treated with an initial dose of 240mg and a maintenance dose of 160mg achieved androgen deprivation from day 28 to the full year. Androgen deprivation achieves disease control in prostate cancer patients.
"Degarelix is one of the first drugs in the emerging novel GnRH blocker class of treatments for prostate cancer and represents a...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Oncology Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.